237 related articles for article (PubMed ID: 27747906)
1. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
2. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
Abubakar MB; Wei K; Gan SH
Pharmacogenet Genomics; 2014 Dec; 24(12):575-81. PubMed ID: 25203739
[TBL] [Abstract][Full Text] [Related]
3. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
4. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
5. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Singh S; Cuzick J; Mesher D; Richmond B; Howell A
Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole.
Kelly CM; Buzdar AU
Expert Opin Drug Saf; 2010 Nov; 9(6):995-1003. PubMed ID: 20923259
[TBL] [Abstract][Full Text] [Related]
8. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
[TBL] [Abstract][Full Text] [Related]
9. A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
Liu L; Bai YX; Zhou JH; Sun XW; Sui H; Zhang WJ; Yuan HH; Xie R; Wei XL; Zhang TT; Huang P; Li YJ; Wang JX; Zhao S; Zhang QY
Int J Mol Sci; 2013 Sep; 14(9):18973-88. PubMed ID: 24065098
[TBL] [Abstract][Full Text] [Related]
10. Effect of simvastatin on the pharmacokinetics of anastrozole.
Bao T; Blackford AL; Stearns V
Breast Cancer Res Treat; 2012 Jan; 131(2):709-11. PubMed ID: 22089963
[TBL] [Abstract][Full Text] [Related]
11. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Mao JJ; Su HI; Feng R; Donelson ML; Aplenc R; Rebbeck TR; Stanczyk F; DeMichele A
Breast Cancer Res; 2011 Jan; 13(1):R8. PubMed ID: 21251330
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Altundag K; Dede D; Harputluoglu H; Gullu I
Joint Bone Spine; 2007 Dec; 74(6):662-3. PubMed ID: 17913550
[No Abstract] [Full Text] [Related]
13. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
[TBL] [Abstract][Full Text] [Related]
14. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
[TBL] [Abstract][Full Text] [Related]
15. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Park IH; Lee YS; Lee KS; Kim SY; Hong SH; Jeong J; Lee H; Ro J; Nam BH
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1263-71. PubMed ID: 21442439
[TBL] [Abstract][Full Text] [Related]
16. Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Barros-Oliveira MDC; Costa-Silva DR; Andrade DB; Borges US; Tavares CB; Borges RS; Silva JM; Silva BBD
Rev Assoc Med Bras (1992); 2017 Apr; 63(4):371-378. PubMed ID: 28614542
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Tanii H; Shitara Y; Horie T
Eur J Clin Pharmacol; 2011 Oct; 67(10):1017-25. PubMed ID: 21494765
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Egawa C; Hirokaga K; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Mitsunobu M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):262-269. PubMed ID: 26411314
[TBL] [Abstract][Full Text] [Related]
20. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Geisler J; King N; Dowsett M; Ottestad L; Lundgren S; Walton P; Kormeset PO; Lønning PE
Br J Cancer; 1996 Oct; 74(8):1286-91. PubMed ID: 8883419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]